AA
Therapeutic Areas
Inhibrx Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ozekibart (INBRX-109) | Ewing Sarcoma | Phase 1 |
| INBRX-106 | Advanced Solid Tumors | Phase 1/2 |
Leadership Team at Inhibrx Biosciences
MP
Mark P. Lappe
Founder, Chief Executive Officer
DM
David Matly
President
KD
Kelly Deck
EVP, Chief Financial Officer
CB
Carlos Bais
EVP, Chief Scientific Officer
DG
Douglas G. Forsyth
Board Member, Audit Committee Chair
JF
Jon Faiz Kayyem
Board Member
KM
Kimberly Manhard
Board Member
KV
Kristiina Vuori
Board Member